NTLA: Post-Collapse Recovery detected on 5 Nov 2026

All prices, scores, and news on this page reflect data available before market open on .

Free example: 1 of 45 setups from the 5 Nov 2026 scan. Subscribers get the full list every trading day by 6 AM ET.

On 5 Nov 2026, our scan flagged NTLA as a post-collapse recovery setup scoring 70 out of 98 (Good tier), with a 66% win probability based on our historical pattern database and a 0.39 to 1 risk to reward profile from the published levels. This is a swing trade setup: win probability reflects a multi-day swing hold, not an intraday move. At $12.31, the conservative target is $12.99 with a stop at $10.57. A further breakout above resistance near $13.94 offers a larger move if momentum continues past the initial target.

70 of 98
Good
66%
Moderate
0.39 : 1
$0.68 to target $1.74 to stop
Swing Trading Plan
Entry
$12.31
$12.99
$10.57
2-8 trading days
Exp. Reward
+$0.37
Exp. Risk
-$0.37

Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.

Current Setup
NTLA is forming a post-collapse recovery pattern off a bottom established around $10.58 (key support). At $12.31, price sits 54.84% above the 52-week low and has recovered 7 days from a bull flag (formed Oct 23, pattern quality 31.4). The setup shows moderate structure (13.9/15) and breakout conviction (12.11/13), with volume at 0.6x average—subdued relative volume undermines the recovery narrative. The 66.49% win probability and 70.01 overall score reflect reasonable setup quality, though volume ratio below 1.0 signals weak participation. RSI at 52.13 is neutral. Next resistance trades at $13.94.
Stock Context
Intellia completed enrollment in its Phase 3 MAGNITUDE-2 trial of nex-z for hereditary transthyretin amyloidosis on November 4, 2026, a pivotal milestone that could accelerate the path to commercialization. The company expects FDA acceptance of its rolling BLA submission for LONVOSI by end of 2026, positioning another regulatory catalyst. However, sentiment shows mixed signals: Barclays initiated Intellia at Underweight on expected commercial headwinds on October 6, while Evercore ISI upgraded to Outperform in August. CEO John Leonard sold 9,000 shares on November 3, which may signal caution ahead of the trial readout. Cash runway extends into 2028, removing near-term funding pressure.
What to Expect
A successful breakout above $13.94 resistance would target the conservative measure of $12.99—modest upside of ~5.5% from current price. The bull flag within this recovery (pattern strength: good) suggests tighter target potential. Historical win probability of 66.49% supports breakout probability, but execution requires volume confirmation above 4.9M shares (20-day average). Volume is currently 40% below average, so breakout conviction would strengthen with above-average volume thrust through resistance. Invalidation occurs below $10.58 support, which would negatively confirm the recovery is reversing.
Risk Factors
NTLA faces a confluence of risks that could derail this setup. Barclays' Underweight rating citing commercial headwinds reflects street skepticism around revenue scaling despite clinical wins. Biotech-sector beta of 1.37 amplifies downside in a bearish market regime (regime score -0.31), while elevated 20-day volatility (73.15%) increases whipsaw risk. Data presentations at medical congresses on November 9 and 18 could trigger volatility. Q2 net loss widened to $106.6M with increased G&A expenses tied to commercial build-out, underscoring cash burn acceleration. Recent CEO selling adds insider-action caution. Volume weakness (0.6x ratio) signals institutional hesitation into breakout attempt.
How We Find and Score This Setup
We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading. What the terms mean →
Frequently Asked Questions
Is NTLA a good swing trade?
NTLA scored 70 out of 98 on our post-collapse recovery scan, with a 66% historical win probability over a 2-8 trading days hold. Good setup based on our systematic scoring.
What is the entry, target, and stop loss for this setup?
The setup's reference price is $12.31, with a conservative target of $12.99 and a stop loss at $10.57.
What would invalidate this post-collapse recovery setup?
A close below the stop loss at $10.57 would invalidate the setup and suggest the pattern has failed.
How is the win probability calculated?
Win probability is a calibrated estimate of how similar historical post-collapse recovery setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.
Market & Sector Regime
Market
Bearish -0.31
-1.0 0 +1.0
Health Care Sector
Bullish 0.83
-1.0 0 +1.0
Other Patterns Detected Today
Bull Flag
7 days in pattern
Good 31.4
Overall Score
35 of 40
Strong
Pattern Quality
14 of 20
Good
Setup
11 of 20
Fair
R/R
10 of 18
Fair
Context
Pattern Quality Score
14 of 15
Exceptional
Structure
12 of 13
Exceptional
Breakout
9 of 12
Good
Volume
Recent Performance
-7.6%
1W
+5.7%
2W
-0.5%
1M
+9.5%
3M
Momentum & Trend
RSI (14)
52.1
Neutral
MACD Histogram
+0.05
Bullish
Bollinger Band Position
61.0%
Mid Zone
Volatility & Risk
20-Day Volatility
0.73
Very High
ATR %
6.7%
High
Beta
1.37
Above Mkt
Volume Analysis
Volume Ratio
0.60x
Below Avg
20-Day Avg Vol
4.9M
shares / day
Current Volume
2.9M
shares traded
Price Levels
52W High
$18.48
Resistance
$13.94
Target
$12.99
Current
$12.31
Support
$10.58
Stop Loss
$10.57
52W Low
$7.95
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.